Neuroprotector Hopeful in Stroke; Late-Pandemic STEMIs; Exercise vs Risky Carotids?
(MedPage Today) -- In the CLEAR Outcomes trial, bempedoic acid (Nexletol) reduced cardiac events to a similar extent as statins, according to a secondary analysis presented at ENDO 2023.
The TLR4 antagonist ApTOLL showed promise as a neuroprotectant...
Source: MedPage Today Cardiovascular - Category: Cardiology Source Type: news
More News: Brain | Cardiology | Cardiovascular | Cholesterol | Heart | Neurology | Pandemics | Sports Medicine | Statin Therapy | Stroke